§
Luxuse
Patent Intelligence
Sign In
← Back to Patent Explorer
US4988698A Expired / Lapsed US ⏱️ 0.0 years remaining

2(1H)-quinolinone compounds and pharmaceutical composition comprising the same

Assignee: Astellas Pharma Inc
•
Filing: 1989-11-13
•
Granted: 1991-01-29
•
Expires: 2009-11-13
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract This invention relates to new 2(1H)-quinolinone compounds having the formula: ##STR1## wherein R 1 is a imidazopyridyl, thiazolyl, indolyl, dihydroindolyl, imidazolyl, benzimidazolyl, quinolyl, isoquinolyl, quinazolinyl, dihydroisoquinolyl, tetrahydroimidazopyridyl or tetrahydroquinolyl, each of which may be substituted with substituents(s) selected from the group consisting of lower alkyl, halogen, lower alkoxy, lower alkylthio, ar(lower)alkoxy, cyano, nitro, amino, lower alkylamino, acylamino, hydroxy and oxo, R 2 is hydrogen, lower alkyl or halogen, A is a single bond or a group of the formula selected from the group consisting of: ##STR2## and --X--CO--, in which X is a single bond or lower alkylene and X 1 is lower alkylene, and a heavy solid line means a single or a double bond, and its pharmaceutically acceptable salt. Said compounds are used in the therapeutic treatment of heart diseases and hypertension in human beings and other animals.

Inventors

  • 👤 Masayuki Kato
  • 👤 Shigetaka Nishino
  • 👤 Kiyotaka Ito
  • 👤 Hisashi Takasugi

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-25 04:31
CPC Classifications
C; C07; C07D; C07D401/00; C07D401/02; C07D401/04; C07D401/12; A; A61; A61P; A61P9/00; A61P9/04; A61P9/06; A61P9/12; C07D215/00; C07D215/02; C07D215/16; C07D215/38; C07D215/48; C07D417/00; C07D417/02; C07D417/12; C07D417/14; C07D471/00; C07D471/02; C07D471/04

Claims Analysis

Total Claims: 7
Claim 1
Independent Claim 115 words
A compound of the formula: ##STR9## wherein R 1 is imidazopyridyl, thiazolyl, indolyl, dihydroindolyl, imidazolyl, benzimidazolyl, quinolyl, isoquinolyl, quinazolinyl, dihydroisoquinolyl, tetrahydroimidazopyridyl or tetrahydroquinolyl, each of which may be substitute with substituent(s) selected from the group consisting of lower alkyl, halogen, lower alkoxy, lower alkylthio, ar(lower)alkoxy, cyano, nitro, amino, lower alkylamino, acylamino, hydroxy and oxo, R 2 is hydrogen, lower alkyl or halogen, A is a single bond or a group of the formula selected from the group consisting of: ##STR10## and --X--CO--, in which X is a single bond or lower alkylene and X 1 is lower alkylene, and a heavy solid line means a single or a double bond, and its pharmaceutically acceptable salt.
Claim 2
Dependent Claim 115 words
A compound of the formula: ##STR9## wherein R 1 is imidazopyridyl, thiazolyl, indolyl, dihydroindolyl, imidazolyl, benzimidazolyl, quinolyl, isoquinolyl, quinazolinyl, dihydroisoquinolyl, tetrahydroimidazopyridyl or tetrahydroquinolyl, each of which may be substitute with substituent(s) selected from the group consisting of lower alkyl, halogen, lower alkoxy, lower alkylthio, ar(lower)alkoxy, cyano, nitro, amino, lower alkylamino, acylamino, hydroxy and oxo, R 2 is hydrogen, lower alkyl or halogen, A is a single bond or a group of the formula selected from the group consisting of: ##STR10## and --X--CO--, in which X is a single bond or lower alkylene and X 1 is lower alkylene, and a heavy solid line means a single or a double bond, and its pharmaceutically acceptable salt.
Claim 3
Dependent Claim 30 words
A compound of claim 1, wherein R 1 is imidazopyridyl substituted with lower alkyl, R 2 is hydrogen, A is --CO--, and a heavy solid line means a single bond.
Claim 4
Dependent Claim 13 words
A compound of claim 2, wherein R 1 is imidazo[1,2-a]pyridyl substituted with methyl.
Claim 5
Dependent Claim 17 words
A compound of claim 3, which is 6-[4-(7-methylimidazo[1,2-a]pyridine-2-carbonyl)-1-piperazinyl]-3,4-dihydro-2(1H)-quinolinone, its monohydrochloride, its dihydrochloride, its methanesulfonate or its hemimaleate.
Claim 6
Dependent Claim 24 words
A pharmaceutical composition comprising a compound of claim 1, as an active ingredient, in association with a pharmaceutically acceptable, substantially nontoxic carrier or excipient.
Claim 7
Dependent Claim 27 words
A method for therapeutic treatment of heart disease or hypertension which comprises administering an effective amount of a compound of claim 1 to human beings or animals.

References Cited (Backward Citations)

US4886809A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1994-01-28 1994-07-30 1995-01-29 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1998-01-28 1998-07-30 1999-01-29 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2002-01-28 2002-07-30 2003-01-29 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag